Transferrin-conjugated nanoparticles of Poly(lactide)-d-α-Tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier

Biomaterials

Volumn 31, Issue 30, 2010, Pages 7748-7757

  Gan, Chee Wee ^a   Feng, Si Shen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Biodegradable polymers; Cancer nanotechnology; Docetaxel; Drug targeting; Nanomedicine; Surface modification

Indexed keywords

CANCER NANOTECHNOLOGY; DOCETAXEL; DRUG-TARGETING; NANOMEDICINES; SURFACE MODIFICATION;

BIODEGRADABLE POLYMERS; BLOCK COPOLYMERS; BLOOD; CONTROLLED DRUG DELIVERY; COPOLYMERIZATION; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYETHYLENES; THERMOPLASTICS;

ORGANIC POLYMERS;

COPOLYMER; COUMARIN; DOCETAXEL; LACTIDE DEXTRO ALPHA TOCOPHERYLPOLYETHYLENE GLYCOL SUCCINATE DIBLOCK COPOLYMER; MACROGOL; NANOPARTICLE; POLYGLACTIN; TRANSFERRIN; TRANSFERRIN LACTIDE DEXTRO ALPHA TOCOPHERYLPOLYETHYLENE GLYCOL SUCCINATE CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; BLOOD BRAIN BARRIER; CELL VIABILITY; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; EX VIVO STUDY; IC 50; MALE; MOLECULAR IMAGING; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; RAT; SURFACE PROPERTY; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; BLOOD-BRAIN BARRIER; BRAIN; COUMARINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MATERIALS TESTING; NANOPARTICLES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SUCCINATES; TAXOIDS; THIAZOLES; TISSUE DISTRIBUTION; TRANSFERRIN;

EID: 77955769665     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.06.053     Document Type: Article

References (54)

1. Behin A., Hoang-Xuan K., Carpentier A.F., Delattre J.Y. Primary brain tumors in adults. Lancet 2003, 361:323-331.
2. Béduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28:4947-4967.
3. Wong T.Z., Coleman R.E. PET imaging in brain tumors. Positron emission tomography. Clinical practice 2006, 79-87. Springer, London. P.E. Valk, D. Delbeke, D.L. Bailey, D.W. Townsend, M.N. Maisey (Eds.).
4. Edwards R.T. Drug delivery via the blood-brain barrier. Nat Neurosci 2001, 4:221-222.
5. Begley D.J., Brightman M.W. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003, 61:39-78.
6. Pardridge W.M. Blood-brain barrier delivery. Drug Discov Today 2007, 12:54-61.
7. Bodor N., Buchwald P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 1999, 36:229-254.
8. Pardridge W.M. Drug targeting to the brain. Pharm Res 2007, 24:1733-1744.
9. Fischer H., Gottschlich R., Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 1998, 165:201-211.
10. Cohen B.E., Bangham A.D. Diffusion of small non-electrolytes across liposome membrane. Nature 1972, 236:173-174.
11. Gelperina S., Maksimenko O., Khalansky A., Vanchugova L., Shipulo E., Abbasova K., et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 2010, 74:157-163.
12. Garcia-Garcia E., Andrieux K., Gil S., Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain?. Int J Pharm 2005, 298:274-292.
13. Miller G. Breaking down barriers. Science 2002, 297:1116-1118.
14. Pardridge W.M., Oldendorf W.H. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta 1975, 401:128-136.
15. Pardridge W.M., Oldendorf W.H. Transport of metabolic substrates through the blood-brain barrier. J Neurochem 1977, 28:5-12.
16. Sahoo S.K., Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharmacol 2005, 2:373-383.
17. Jones A.R., Shusta E.V. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007, 24:1759-1771.
18. Frank H.J., Pardridge W.M., Jankovic-Vokes T., Vinters H.V., Morris W.L. Insulin binding to the blood-brain barrier in the streptozotocin diabetic rat. J Neurochem 1986, 47:405-411.
19. Duffy K.R., Pardridge W.M. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987, 420:32-38.
20. Descamp L., Dehouck M.P., Torpier G., Cecchelli R. Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. Am J Phys 1996, 270:1149-1158.
21. Dehouck B., Fenart L., Dehouck M.P., Pierce A., Torpier G., Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J Cell Biol 1997, 138:877-889.
22. Gatter K.C., Brown G., Trowbridge I.S., Woolston R.E., Mason D.Y. Transferrin receptors in human tissues; their distribution and possible clinical relevance. J Clin Pathol 1983, 36:539-545.
23. Wagner E., Curiel D., Cotton M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv Drug Deliv Rev 1994, 14:113-135.
24. Högemann-Savellano D., Bos E., Blondet C., Sato F., Abe T., Josephson L., et al. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 2003, 5:495-506.
25. ® P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target 2009, 17:533-542.
26. Niitsu Y., Kohgo Y., Nishisato T., Kondo H., Kato J., Urushizaki Y., et al. Transferrin receptors in human cancerous tissues. Tohoku J Exp Med 1987, 153:239-243.
27. Li H., Qian Z.M. Transferrin/transferrin receptor-mediated drug elivery. Med Res Rev 2002, 22:225-250.
28. Nakase I., Gallis B., Takatani-Nakase T., Oh S., Lacoste E., Singh N.P., et al. Transferrin receptor-dependent cytotoxicity of artemisinin-transferrin conjugates on prostate cancer cells and induction of apoptosis. Cancer Lett 2009, 274:290-298.
29. Gomme P.T., McCann K.B. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005, 10:267-273.
30. Teehan G.S., Bahdouch D., Ruthazer R., Balakrishnan V.S., Snydman D.R., Jaber B.L. Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 2004, 38:1090-1094.
31. Visser C.C., Stevanovié S., Heleen Voorwinden L., Gaillard P.J., Crommelin D.J., Danhof M., et al. Validation of the transferrin receptor for drug targeting to the brain capillary endothelial cells in vitro. J Drug Target 2004, 12:145-150.
32. Roberts R.L., Fine R.E., Sandra A. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J Cell Sci 1993, 104:521-532.
33. Fishman J.B., Rubin J.B., Handrahan J., Connor J.R., Fine R.E. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 1987, 18:299-304.
34. Broadwell R.D., Baker-Cairns B.J., Friden P.M., Olivier C., Villegas J.C. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp Neurol 1996, 142:47-65.
35. Ying X., Wen H., Lu W.L., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010, 141:183-192.
36. Gupta Y., Jain A., Jain S.K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007, 59:935-940.
37. Ulbrich K., Hekmatara T., Herbert E., Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009, 71:251-256.
38. Muthu M.S., Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine 2009, 4:105-118.
39. Monsky W.L., Fukumura D., Gohongi T., Ancukiewcz M., Weich H.A., Torchilin V.P., et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999, 59:4129-4135.
40. Müller R.H., Ruhl D., Luck M., Paulke B.-R. Influence of fluorescent labeling of polystyrene particles on phagocytic uptake, surface hydrophobicity, and plasma protein adsorption. Pharm Res 1997, 14:18-27.
41. Owen D.E., Peppas N.A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006, 307:93-102.
42. Salvador-Morales C., Zhang L., Langer R., Farokhzad O.C. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009, 30:2231-2240.
43. Letchford K., Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007, 65:259-269.
44. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001, 47:65-81.
45. Petri B., Bootz A., Khalansky A., Hekmatara T., Muller R., Uhl R., et al. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release 2007, 117:51-58.
46. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across blood-brain barrier. J Drug Target 2002, 10:317-325.
47. Debotton N., Pames M., Kadouche J., Benita S. Overcoming the formulation obstacles towards targeted chemotherapy: In vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles. J Control Release 2008, 127:219-230.
48. Zhang Z., Feng S.-S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: Synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27:262-270.
49. Lee S.H., Zhang Z., Feng S.S. Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials 2007, 28:2041-2050.
50. Müller R.H. Charge determinations. Colloidal carriers for controlled drug delivery and targeting: modification, characterization and in vivo distribution 1991, 57-97. CRC Press, Florida. R.H. Müller (Ed.).
51. Bickel U., Yoshikawa T., Pardridge W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001, 46:247-279.
52. Hu K., Li J., Shen Y., Lu W., Gao X., Zhang Q., et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations. J Control Release 2009, 134:55-61.
53. Xu Z., Gu W., Huang J., Sui H., Zhou Z., Yang Y., et al. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 2005, 288:361-368.
54. Chang J., Jallouli Y., Kroubi M., Yuan X.-B., Feng W., Kang C.-S. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 2009, 379:285-292.